Symphony Financial Ltd. Co. Sells 264 Shares of Amgen Inc. (NASDAQ:AMGN)

Symphony Financial Ltd. Co. decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,559 shares of the medical research company’s stock after selling 264 shares during the period. Symphony Financial Ltd. Co.’s holdings in Amgen were worth $2,761,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. AdvisorNet Financial Inc grew its position in Amgen by 5.7% in the first quarter. AdvisorNet Financial Inc now owns 2,206 shares of the medical research company’s stock worth $627,000 after acquiring an additional 119 shares in the last quarter. Austin Private Wealth LLC increased its position in shares of Amgen by 4.3% during the 1st quarter. Austin Private Wealth LLC now owns 1,023 shares of the medical research company’s stock valued at $281,000 after purchasing an additional 42 shares during the last quarter. Dynamic Advisor Solutions LLC raised its holdings in shares of Amgen by 2.0% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 22,573 shares of the medical research company’s stock valued at $6,418,000 after buying an additional 432 shares in the last quarter. DLK Investment Management LLC lifted its position in Amgen by 1.4% in the 1st quarter. DLK Investment Management LLC now owns 19,104 shares of the medical research company’s stock worth $5,432,000 after buying an additional 260 shares during the last quarter. Finally, Hoxton Planning & Management LLC lifted its position in Amgen by 5.7% in the 1st quarter. Hoxton Planning & Management LLC now owns 739 shares of the medical research company’s stock worth $210,000 after buying an additional 40 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Stock Up 1.2 %

AMGN stock traded up $3.92 during midday trading on Tuesday, hitting $320.66. The stock had a trading volume of 991,404 shares, compared to its average volume of 2,436,352. The business has a 50-day moving average of $326.00 and a two-hundred day moving average of $312.76. The firm has a market cap of $172.01 billion, a price-to-earnings ratio of 45.06, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. Amgen Inc. has a 52-week low of $249.70 and a 52-week high of $346.85.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by ($0.04). The company had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. The business’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.00 EPS. As a group, equities research analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a $2.25 dividend. The ex-dividend date was Friday, August 16th. This represents a $9.00 annualized dividend and a yield of 2.81%. Amgen’s payout ratio is 128.57%.

Analyst Ratings Changes

Several research firms have commented on AMGN. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price target (up from $375.00) on shares of Amgen in a research note on Wednesday, August 7th. Robert W. Baird restated an “underperform” rating and set a $215.00 price target on shares of Amgen in a research report on Wednesday, September 25th. Barclays lifted their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Dbs Bank upgraded Amgen to a “strong-buy” rating in a report on Monday, September 16th. Finally, Wells Fargo & Company downgraded Amgen from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen presently has a consensus rating of “Moderate Buy” and a consensus price target of $332.55.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.